Eton Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	32.64	22.89	23.33	0.04	0.96	0
Revenue Growth (YoY)	42.60%	-1.89%	59725.64%	-95.93%	-	-
Cost of Revenue	10.58	6.93	2.83	0.44	0.45	0
Gross Profit	22.06	15.96	20.51	-0.4	0.51	0
Selling, General & Admin	18.93	18.58	14.27	12.61	7.55	4.69
Research & Development	3.32	4	6.24	14.1	11.56	5.63
Operating Expenses	22.25	22.58	20.5	26.71	19.11	10.32
Operating Income	-0.19	-6.62	0.01	-27.11	-18.6	-10.32
Interest Expense / Income	-0.5	0.76	1.01	0.86	-0.28	-0.16
Other Expense / Income	1	1.64	0.95	-	-	2.58
Pretax Income	-0.69	-9.02	-1.96	-27.97	-18.32	-12.74
Income Tax	0.25	0	0	0	0	0
Net Income	-0.94	-9.02	-1.96	-27.97	-18.32	-12.74
Preferred Dividends	0	0	0	0	0	24.49
Net Income Common	-0.94	-9.02	-1.96	-27.97	-18.32	-37.23
Shares Outstanding (Basic)	26	25	25	21	18	6
Shares Outstanding (Diluted)	26	25	25	21	18	6
Shares Change	1.98%	-0.24%	19.98%	18.29%	176.74%	-
EPS (Basic)	-0.04	-0.36	-0.08	-1.33	-1.03	-5.80
EPS (Diluted)	-0.04	-0.36	-0.08	-1.33	-1.03	-5.80
Free Cash Flow	6.82	4.78	-4.03	-22.4	-19.12	-8.38
Free Cash Flow Per Share	0.27	0.19	-0.16	-1.07	-1.08	-1.31
Gross Margin	67.58%	69.71%	87.88%	-1017.95%	52.76%	-
Operating Margin	-0.59%	-28.92%	0.02%	-69515.38%	-1939.62%	-
Profit Margin	-2.87%	-39.41%	-8.38%	-71717.95%	-1910.32%	-
Free Cash Flow Margin	20.88%	20.89%	-17.27%	-57425.64%	-1993.95%	-
EBITDA	-0.29	-6.49	-0.49	-26.46	-18.15	-12.84
EBITDA Margin	-0.89%	-28.33%	-2.09%	-67846.15%	-1893.01%	-
Depreciation & Amortization	0.9	1.77	0.46	0.65	0.45	0.06
EBIT	-1.19	-8.26	-0.95	-27.11	-18.6	-12.9
EBIT Margin	-3.65%	-36.08%	-4.07%	-69515.38%	-1939.62%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).